PubMed Health⌕ Search

Biomedical subjects

Heng Cui

Publications and source records attributed to Heng Cui.

17 recordsLinked to original sources
PubMed2006

Use of proteomic analysis of endometriosis to identify different protein expression in patients with endometriosis versus normal controls.

OBJECTIVE: To use proteomic techniques, including two-dimensional electrophoresis (2-DE), Western blot, and mass spectrometry, to screen and identify proteins that were expressed differently in patients with endometriosis versus normal controls. DESIGN: First, we aimed to find a difference in the way serum and eutopic endometrial proteins were expressed in women with and without endometriosis. Second, we were interested in searching for endometriotic proteins, which were specifically recognized by sera from patients with endometriosis. SETTING: Collaborative investigation in an academic research environment. PATIENT(S): Consenting women of reproductive age taking no medications and with laparoscopically proven endometriosis. INTERVENTION(S): Surgical excision of eutopic and ectopic endometrial biopsy and phlebotomization of patients with endometriosis and controls. MAIN OUTCOME MEASURE(S): Protein expression. RESULT(S): Thirteen protein spots from serum correlated with 11 known proteins and 11 protein spots from endometrium correlated with 11 known proteins were found differently expressed between women with and without endometriosis. Some proteins may be cytoskeletons, and some may be involved in the regulation of cell cycle, signal transduction, or immunological function. Three proteins, which were identified as vimentin, beta-actin, and ATP synthase beta subunit, hybridized significantly differently between endometriosis sera and normal sera. CONCLUSION(S): The data help to establish a human endometriosis proteome database and broaden our understanding of the pathogenesis of endometriosis. Further study of the proteins identified herein will assist in the eventual development of new diagnoses and treatments for endometriosis.

Actins↗
PubMed2006

Humoral immune responses induced by anti-idiotypic antibody fusion protein of 6B11scFv/hGM-CSF in BALB/c mice.

BACKGROUND: We have previously developed and characterized a monoclonal anti-idiotype antibody, designated 6B11, which mimics an ovarian carcinoma associated antigen OC166 - 9 and whose corresponding monoclonal antibody is COC166 - 9 (Ab1). In this study, we evaluate the humoral immune responses induced by the fusion protein 6B11 single-chain variable fragment (scFv)/human granulocyte macrophage colony-stimulating factor (hGM-CSF) and 6B11scFv in BALB/c mice. METHODS: The fusion protein 6B11scFv/hGM-CSF was constructed by fusing a recombinant single-chain variable fragment of 6B11scFv to GM-CSF. BALB/c mice were administrated by 6B11scFv/hGM-CSF and 6B11scFv, respectively. RESULTS: The fusion protein 6B11scFv/hGM-CSF retained binding to the anti-mouse F (ab) 2' and was also biologically active as measured by proliferation of human GM-CSF dependent cell TF1 in vitro. After immunization with the 6B11scFv/hGM-CSF and 6B11ScFv, BALB/c mice showed significantly enhanced Ab3 antibody responses to 6B11scFv/hGM-CSF compared with the 6B11scFv alone. The level of Ab3 was the highest after the first week and maintained for five weeks after the last immunization. Another booster was given when the Ab3 titer descended, and it would reach to the high level in a week. CONCLUSION: The fusion protein 6B11scFv/hGM-CSF can induce humoral immunity against ovarian carcinoma in vivo. We also provide the theoretical foundation for the application of the fusion protein 6B11scFv/hGM-CSF for active immunotherapy of ovarian cancer.

Animals↗
PubMed2006

[Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody].

OBJECTIVE: To probe better immunization dose and interval of anti-idiotypical minibody (6B11 minibody) in animals and to guide the clinical trials of ovarian epithelial cancer treatment. METHODS: Minibody was induced with isopropylthiogalactoside (IPTG) in E.coli and analyzed with direct enzyme linked immunosorbent assay (ELISA). Normal BALB/c mice were randomly divided into groups A, B, C, D, E, F, immunized with the murine monoclonal anti-idiotypic antibody 6B11 minibody 150 microg, 100 microg, 50 microg, and mice IgG 100 microg, human IgG 100 microg, phosphate buffered saline (PBS) 100 microl at d(1), d(14), d(28) respectively. Anti-anti-idiotypic antibody (Ab3) level was tested and antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effect of mouse spleen cells to human ovarian carcinoma SKOV3 cells were measured using (51)Cr-release assay. UV absorption values were tested at 490 nm. RESULTS: 6B11 minibody was successfully expressed on E.coli and could react with a murine monoclonal antibody COC166-9. Ab3 could not be detected until one week after d(14)'s boost, its level gradually elevated and peaked one week after d(28)'s boost, and maintained at high level for about six weeks then declined dramatically seven weeks after d(28)'s boost. When boosted again at seven weeks after d(28)'s boost, the Ab3 level elevated quickly one week after, and maintained at this level at least for two weeks. The Ab3 level of group B was higher than groups A and C, mean A (absorption) value during six weeks after d(28)'s boost was 1.05 in group A, 1.06 in group B, 0.94 in group C, and there was no significant difference (P > 0.05). At four different effector cell/target cell (E/T) ratios, the ADCC was highest in group A and lowest in group C; when the E/T ratio was 1:125, (51)Cr releasing rate was 23% in group A, 17% in group B, and 12% in group C, the difference between groups A, B, C had statistical significance (P < 0.05). When serum was diluted at 1:50, the CDC effects were higher in group A and B than in group C ((51)Cr releasing rate was 47%, 39%, 26% respectively; P < 0.05), but there was no significant difference between groups A and B (P > 0.05). CONCLUSION: 6B11 anti-idiotypic minibody of ovarian carcinoma can be used as tumor vaccine, the suitable immunization protocol in animals may be: prime at d(1), d(14) and d(28) at a dose of 100 microg; prime interval is six weeks.

Animals↗
PubMed2005

[In vitro study of the antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].

OBJECTIVE: To evaluate whether anti-tumor immune response can be induced in vitro with 6B11 anti-idiotypic minibody. and to explore its probability as ovarian cancer vaccine. METHODS: Separated human peripheral blood mononuclear cells (PBMC) were stimulated and cultured by 6B11 minibody. The proliferations of PBMC and cytotoxin were observed by (3)HTdR and (51)Cr release test respectively. ELISA(Enzyme-Linked Immunosorbent Assay) test and Immune Flow Cytometry were used to analyze IFN-gamma in supernatant of the cultured cdlls and the change of T lymphocyte phenotype of PBMC with 6B11 minibody stimulated. RESULTS: 6B11 minibody could stimulate PBMC to proliferate, the best dose was 20 mg/L; it performed cytotoxin function to ovarian carcinoma cell line expressing OC166-9. IFN-gamma maintained at high level after stimulation. It stimulated proliferation of CD3(+) T cell and CD4(+) from PBMC after stimulation respectively. CD8(+) T cell proliferation was not clear. There was significant difference between stimulation and unstimulation in CD4(+)/CD8(+) ratio. CONCLUSION: 6B11 anti-idiotypic minibody can induce both humoral and cellular immunity against ovarian carcinoma in vitro. This paper has provided strong experimental evidence for clinical use of 6B11 minibody as anti-idiotype vaccines against ovarian carcinoma.

Antibodies, Anti-Idiotypic↗
PubMed2005

[A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer].

OBJECTIVE: To compare the efficacy of combination regiments of taxol given weekly plus carboplatin and taxol given every three weeks plus carboplatin. To observe the toxicity of the two regiments. To observe the two-year survival rate in the two groups. METHODS: Total 125 eligible patients in 13 centers of CGOG were entered into the two arms of this randomized clinical trial, of whom 51 were entered into weekly taxol group and 74 entered into 3 weeks taxol group. RESULTS: 81.6% (102/125) of patients had satisfactory decreasing of CA125 level after optimal cytoreductive surgery and chemotherapy. 86.3% (44/51) of patients is in weekly group and 78.4% (58/74) of patients in three weeks group (P > 0.05). Relapse frequency is 29.7% in every three weeks group and 19.6% in weekly group (P > 0.05). Median interval to relapse is 15.7 months in every three weeks group and 13.6 months in weekly group (P > 0.05). One-year survival rate is 95.2% in every three weeks and 93.9% in weekly group (P > 0.05). Two-year survival rate is 78.7% in every three weeks and 85.3% in weekly group (P > 0.05). Grade III and IV myelosuooression is 45.9% in three weeks group and, 27.5% in weekly group (P < 0.05). CONCLUSION: (1) The two regiments had equal efficacy. (2) Myelosuppression was less frequency in the weekly group than in every three weeks group. (3) Weekly taxol therapy has mild toxicity and is more suitable for the old and feeble patients. Weekly taxol therapy can be conveniently administered in outpatients department.

Adult↗
PubMed2005

[Clinical management and prognostic analysis of primary peritoneal neoplasms].

OBJECTIVE: To investigate the clinical management strategies and prognostic factors of primary peritoneal neoplasms. METHODS: We retrospectively reviewed the clinical and pathological records of 24 cases with primary peritoneal neoplasms treated in the People's Hospital, Peking University during May 1995 and April 2004. RESULTS: Among 24 cases, 15 patients were diagnosed as serous papillary adenocarcinoma (9 highly and intermediately differentiated, and 6 lowly differentiated), 6 as mixed epithelial carcinoma and 3 as mixed malignant Mullerian tumor (MMMT). All patients underwent cytoreductive surgery, 21 cases having, suboptimal debulking one. Then they received a platinum-based chemotherapy. Thirteen cases received paclitaxel + cisplatin (TP) and 9 received cisplatin + doxorubicin + cyclophosphamide (PAC) combination chemotherapy. The primary response reached 80% (complete response 55% and partial response 25%). The median survival of all patients was 42 months (95% CI = 22-62 months). Survival for patients with primary peritoneal serous papillary carcinoma (PPSPC), mixed epithelial carcinoma and MMMT was 44, 19 and 13 months respectively, with a significant difference between PPSPC and MMMT (P < 0.05). Patients receiving TP combination also exhibited longer survival than those receiving PAC regimen (mean survival 75 vs 28 months, P < 0.05). CONCLUSIONS: Patients with primary peritoneal neoplasms should be treated with appropriate cytoreductive surgery. A primary surgical protocol is bilateral salpingo-oophorectomy and omentectomy. Overestimating an optimal debulking surgery may have no benefit on the survival. TP combination therapy may bring longer survival than PAC regimen. Histopathologic types and chemotherapy regimens are the essential factors of the prognosis.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed2004

[Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice].

BACKGROUND & OBJECTIVE: Ovarian carcinoma is leading cause of death in gynecologic malignancies. The survival rate cannot be improved after routine surgery, chemotherapy, and radiotherapy. Therefore biotherapy becomes the fourth treatment pattern for ovarian carcinoma. Adequate experimental models for the development of biologic therapeutic strategies are needed. Our purpose was to establish and compare two intraperitoneally transplanted human ovarian carcinoma models with human immune reconstitution in severe combined immunodeficient (SCID) mice. METHODS: Six and ten C.B17/SCID mice were intraperitoneally injected with human ovarian adenocarcinoma SKOV3 and SKOV3.ip1 cells, respectively. Their biological, histological, and immunological features were compared. Ascites of the mice in SKOV3.ip1 group was injected into other six mice. All the 22 SCID mice were intraperitoneally injected with human peripheral blood lymphocytes (PBL) to establish immune reconstituted model. RESULTS: The taken rates of the SKOV3 and SKOV3.ip1 groups were both 100%. The latent periods of tumor growth were 20-41 days and 22-30 days, respectively (P >0.05). While the mean survival time were 50-78 days and 32-43 days, respectively (P< 0.0001). 83.3% (5/6) of the mice injected with ascites of the mice in SKOV3.ip1 group successfully formed new tumor mass and ascites. Autopsy showed the tumors of the two models were widespread in pelvic cavity. The SKOV3.ip1 group also had 0.35-5.60 ml bloody ascites that was similar to the clinical behavior of most patients, while only 0.2 ml in one mice of SKOV3 group. Histological results showed the tumors of the two groups remained the characteristics of serous papillary adenocarcinoma of human ovary, and immunohistochemistry staining showed the ovarian associated antigen OC166-9 were both positive. Human IgG were detected in 72.7% (16/22) of the mice, and human CD4(+) and CD8(+) T cells were positive in 54.5% (12/22) of the mice. CONCLUSION: The two intraperitoneally transplanted human ovarian carcinoma models had been established in human PBL reconstituted SCID mice. The SKOV3.ip1 model may be an ideal animal model for biotherapy research of ovarian carcinoma as it simulates the intraperitoneally disseminating behavior of human ovarian carcinoma in the patients with immune function, and it took relatively shorter time to be established.

Animals↗
PubMed2004

[In vivo study of antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].

BACKGROUND & OBJECTIVE: 6B11 anti-idiotypic minibody can be constructed by fusion of anti-idiotypic single chain antibody (6B11scFv) to human IgG(1) hinge and CH3, which can simulate the function of ovarian carcinoma antigen. It has immune activity of both 6B11 and human immunoglobulin IgG(1) Fc. This study was designed to evaluate whether anti-tumor immune response can be induced in BALB/c mice immunized with 6B11anti-idiotypic minibody and explore its probability as ovarian cancer vaccine. METHODS: BALB/c mice were immunized repeatedly by 6B11 anti-idiotypic minibody. Competition inhibition test, indirect ELISA test, and immune flow cytometry were used for analyzing the serum characterization of anti-anti-idiotypic antibody (Ab3) and the changes of T lymphocyte phenotype of spleen. RESULTS: The specific antitumor immune response could be induced in BALB/c mice after immunized with anti-idiotypic minibody without carrier proteins and adjuvant. The Ab3 maintained at a high level till 30 day after the last immunization. It stimulated proliferation of CD4+ T cells and CD8+ T cells from the spleen of BALB/c mice on 4th day, 14th day, 24th day, and 30th day after the last immunity respectively. CONCLUSIONS: 6B11 anti-idiotypic minibody can induce both humoral and cellular immunity against ovarian carcinoma in vivo, which provided experimental evidence for clinical use of fusion protein 6B11 minibody as anti-idiotype vaccines against ovarian carcinoma.

Animals↗
PubMed2004

[Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].

BACKGROUND & OBJECTIVE: Immunotherapy of sensitizing dendritic cells (DCs) with antigen,protein,and frozen cancer cell has been widely used in treating various cancers. The 6B11 anti-idiotype-antibody,a fusion protein prepared by our research center,can mimic ovarian cancer-associated antigen OC166-9. This study was to induce T cell cytotoxicity against autologous tumor cells of patients with ovarian cancer by 6B11 anti-idiotype-antibody. METHODS: Peripheral blood samples were collected from 10 patients with epithelial ovarian cancer,Monocytes were isolated and cultured to obtain DCs. Immature DCs were stimulated with 6B11 anti-idiotype-antibody (MINI-DC group); unpulsed DCs (unpulsed-DC group),mouse F(ab) '2 fragments pulsed DCs [F(ab)'2-DC group],and T cells alone (T group) were served as controls. Mature DCs were harvested. (3)H-thymidine ((3)H-TdR) incorporation approach was used to measure effect of DCs on stimulating auto-T cell proliferation. Cytotoxicity of DC-activated T cells against auto-tumor cells was measured with (51)Cr 6-h release test,tumor cell lines,SKOV3,HLE,and K562, were used as controls. RESULTS: In 4 cases,cpm value of (3)H-TdR incorporation,as symbol of auto-T cell proliferation, in MINI-DC group was significantly higher than those in control groups. In 5 cases,specific cytotoxicity effect of T cells on auto-tumor cells was observed in MINI-DC group at effect-target ratio of 20:1,the toxicity effect of T cells in MINI-DC group was 25%-100%,significantly higher than those in F(ab)'2-DC group (18%-40%), unpulsed-DC group (13%-43%),and T group (9%-58%). In 4 cases,the toxicity effect of T cells in MINI-DC group, at effect-target ratio of 20:1,on auto-tumor cells was 25%-100%, higher than those on SKOV3 cells (5%-51%),HLE cells (2%-38%),and K562 cells (2%-25%). Moreover,the toxicity effect of T cells in MINI-DC group on auto-tumor cells can be partially blocked by anti-MHC-I antibody,which indicated that the toxicity was antigen-specific. CONCLUSION: DCs loaded with 6B11 anti-idiotype antibody that mimic ovarian cancer antigen can induce antigen specific T cell cytotoxicity against auto-ovarian tumor cells in vitro.

Adult↗
PubMed2003

Preparation of humanized ovarian carcinoma anti-idiotypic minibody.

Murine anti-idiotypic monoclonal antibody (MAb) 6B11 mimicking the tumor-associated antigen OC166-9 is used as a vaccine for the induction of an anti-tumoral immunity in experiments of in vitro and in vivo animal model with ovarian carcinoma. In this article, we have humanized 6B11 anti-idiotypic minibody using overlap polymerase chain reaction (PCR) and DNA recombinant technique, prokaryotic expression vector was produced by genetic fusion of 6B11V(L)-V(H) to human IgG1 hinge and CH3 region. Transformed E. coli BL21(DE3) were propagated and induced by isopropyl-beta D-thiogalactopyranoside (IPTG). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that a protein band with molecular weight of 50kD appeared as the expected size after transformation. Molecular weight of 100 kDa may be examined by electrophoresis in nondenaturing systems. The fusion protein was analyzed with enzyme-linked immunosorbant assay (ELISA), inhibition ELISA tests and Western blot, respectively. The humanized anti-idiotype minibody showed capacity of bivalent binding to ovarian cancer MAb COC166-9 and goat anti-human immunoglobulin IgG1. It is useful reagents for clinical use.

Animals↗
PubMed2003

[Clinical and pathological features of borderline ovarian tumors].

OBJECTIVE: To study the relationship between clinical pathological factors and prognosis. METHODS: Thirty-four cases with borderline ovarian tumors (BOT) and 30 cases with stage I ovarian epithelial cancer admitted in our hospital from Jan.1973 to Dec.2000 were studied retrospectively. All the cases were diagnosed according to the International Histological Classification and Staging of Ovarian Tumors (WHO, 1999). RESULTS: Thirty-seven cases were finally diagnosed of BOT, 6 cases with "microinvasive" had been misinterpreted as stage I ovarian cancer and one had "non-invasive peritoneal implants". Serous (38%) and mucinous (51%) tumors were dominant type of BOT and 95% of tumors were at stage I (International Federation of Gynecology and Obstetrics, FIGO). All patients were operated, 11 cases given conservative surgery with a recurrence rate of 9%, 26 cases had adjuvant chemotherapy, cyclophosphamide + adriamycin + cis-platinum used mostly. 5-year and 10 year survival rates were both 100%. The prognosis of BOT is related to pathology and adjuvant therapy. CONCLUSION: Surgery is the main treatment choice of BOT, and the criteria of chemotherapy must be adequately used.

Adolescent↗
PubMed2003

[Monitoring novel ovarian carcinoma associated genes using cDNA expression microarray].

OBJECTIVE: To explore the gene expression pattern of sample of human ovarian carcinoma. METHOD: The difference in gene expression between normal and neoplastic human ovarian tissues were investigated, we described the assembly and utilization of a 512 member cDNA microarray. RESULT: Thirty-seven genes expressed in ovarian cancer were screened out, 14 genes were up-regulated, 23 genes were down-regulated. CONCLUSION: cDNA microarray for analysis of gene expression pattern is an effective method to identify novel ovarian cancer associated genes.

Female↗
PubMed2003

[Immuno-therapeutic study of anti-idiotype minibody (single chain Fv-CH3) on ovarian carcinoma bearing mice].

OBJECTIVE: An anti-idiotypic minibody with optimal antigenicity which mimicking ovarian cancer antigen was used for therapeutic research in mice model bearing ovarian cancer. METHODS: Using gene engineering technique, prokaryotic expression vector was constructed by genetic fusion of 6B11scFv to human IgG1 hinge and CH3 region. The fusion protein named minibody was induced with IPTG in E. coli and analyzed with Western blot and inhibition ELISA tests respectively. Twenty human-PBL-SCID mice bearing i.p. Skov3.ip1 cells were divided into two groups (10 per-group), 10 mice were immunized repeatedly by minibody every two weeks for three times. Indirect ELISA test was employed for analyzing the characterization of anti-anti-idiotypic scFv (Ab3). The latent period of ascites growth and the mean survival time were observed respectively. CD4+ and CD8+ T cells from the spleen of immunized mice were assayed by flow cytometry. RESULTS: SDS-PAGE gel electrophoresis showed that a protein band with molecular weight of 50,000 appeared as the expected size after transformation and induction the host bacteria BL21 (DE3). The expressed minibody could be reacted with COC166-9 (Ab1 of 6B11) and binding goat anti-human IgG1 antibody in Western blot. Inhibition ELISA showed minibody had the capacity of binding ovarian cancer monoclonal antibody COC166-9 instead of primal antigen. Ab3 could be detected in the sera of immunized mice with minibody by ELISA test. Ab3 reached the highest at the 14th day after last vaccination and lasted for 6 weeks. The ratio of CD4+/CD8+ was the highest at the 13th day after last vaccination. The latent period of ascites growth were (37.7 +/- 5.5) days and (48.6 +/- 14.3) days (P = 0.04) respectively; while the mean survival time were (42.5 +/- 1.8) days and (59.4 +/- 16.8) days (P = 0.011) in the control and minibody group respectively. CONCLUSIONS: These results demonstrate the successful construction and expression minibody with good immune activities of 6B11scFv and human IgG1 molecules function. Antigenicity is increased without adjuvants and partial humanization is realized. Minibody can induce humoral anti-idiotypic immunity responses against ovarian carcinoma in vivo. When ascites formation was delayed or prevented and the survival was prolonged in minibody group. We expect that minibody may be used as tumor vaccine to ovarian carcinoma in the future clinical trails.

Animals↗
PubMed2003

[Development of tumor vaccine on gynecologic cancer].

The study of tumor vaccine is one of the focus of immunological therapy on malignant gynecologic cancer. All of the ovarian carcinoma vaccine are therapeutic, including cloned antigen vaccine, tumor cell vaccine, genetic engineering tumor cell vaccine, dendritic cell (DC) vaccine, as well as anti-idiotypic vaccine. The therapeutic vaccines based on human papillomavirus (HPV) of cervical cancer are mostly summarized, including polypeptides vaccine, carrier vaccine, fusion protein or chimeric vaccine, and DC vaccine. The preventive vaccine based on HPV of cervical cancer are briefly introduced. As there are only a few reports on endometrial carcinoma vaccine.

Cancer Vaccines↗
PubMed2002

[Clinical effect of femoral cannulation via artificial vessel in operation for aortic dissection].

OBJECTIVE: To evaluate the effect of femoral cannulation via artificial vessel in operation for aortic dissection. METHODS: Operation through femoral cannulation via artificial vessel was performed upon 159 patients with aortic dissection, 89 of Stanford type A and 70 of Stanford type B. An artificial vessel was anastomosed end-to-side to the femural artery. Femoral catheter was inserted via this artificial vessel. Cardiopulmonary bypass was performed in 90 patients, among which 31 had deep hypothermic circulatory arrest. Left heart bypass was performed in 69 patients. RESULTS: False lumen perfusion was detected during cardiopulmonary bypass in 7 patients (4.4%). Cerebral events occurred in 7 patients (two patients with diffused cerebral anoxia with one death, and five patients with cerebral embolism with three deaths). 12 patients suffered from prolonged incision recovery (9.0%), and two from local infection (1.5%). No lower extremity ischemia or femoral thrombosis was found in the cannulation side. CONCLUSION: Femoral cannulation via artificial vessel effectively reduces the incidence of structure of femoral artery, thrombosis, and lower extremity ischemia. Operation through femoral cannulation via artificial vessel is very effective in treatment of aortal dissection. Only a few cases of cerebral events caused by retrograde perfusion through femoral cannulation occurred in this group, however, with high mortality.

Adult↗